NIT1

Across TCGA pan-cancer cohorts, NIT1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NIT1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NIT1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIT1 expression acts as an unfavorable survival marker.

BLCA, LUSC, and LUAD are the cancer types where NIT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.194	0.628	.001	18	view →
LUSC	OS	Median	All	0.081	0.818	<.001	12	view →
LUAD	DFS	Median	All	0.206	0.767	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NIT1–BLCA (DFS)

Open the BLCA breakdown →